Remibrutinib clears pivotal multiple sclerosis tests with no liver safety signal as Novartis eyes approvals
Remibrutinib wins two Phase III multiple sclerosis trials as Novartis prepares global filings. See what the results mean for the BTK race.
Pharma & Biotech
Pharma & Biotech
Novartis remibrutinib beats teriflunomide in two Phase 3 multiple sclerosis trials
Novartis says oral BTK inhibitor remibrutinib significantly reduced relapse rates and MRI lesions versus teriflunomide in both Phase 3 REMODEL trials, with no liver safety signal and global regulatory filings now planned.